Moonlight Therapeutics $3M CRO Battle Card
Moonlight just snagged $3M IND funding. Use this battle card to fuel your CRO pipeline. Contact CEO Samir Patel for your next touch and close fast.
Published on
Do not index
Do not index
🚀 Battle Card: Moonlight Therapeutics
Quick trigger: $3M funding (2025-10-17). Leverage this Moonlight Therapeutics sales trigger to position your trial services fast.
👤 Decision Maker in the News
- Samir Patel, CEO 📧 samir.patel@moonlighttx.com
💡 Why It Matters
- FDA cleared the IND for MOON101 and secured new DHA & NIAID funding → Source Another potent Moonlight Therapeutics sales trigger for CRO adoption.
🎯 Core Pain Point
- Regulatory complexity of initiating first-in-human peanut allergy trials
- Funding gaps to expand pipeline beyond MOON101
💰 What to Pitch
- Primary: IND & clinical trial management (CRO services) → accelerate SURVEYOR trial launch
- Expansion: Grant writing & regulatory consulting → unlock DHA & NIAID cooperative funding
🗺️ Quick Context
- HQ: Atlanta, GA
- Employees: ≈ 30
- Rev: ≈ $1 M
- Website: moonlighttx.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Moonlight Therapeutics’ business.*
- Parexel — CRO / Clinical Trial Ops
- Unique edge: Deep IND and early-phase expertise
- Evaluated by CEO & Head of Clinical
- ICON — CRO / Global Trials
- Unique edge: Scaled patient recruitment networks
- Evaluated by VP Operations for enrollment speed
- Medpace — CRO / End-to-End Solutions
- Unique edge: Integrated lab and central monitoring
- Evaluated by Head of Clinical & Finance
- Covance (Labcorp) — Lab Services / Preclinical
- Unique edge: Broad assay and bioanalytical capabilities
- Evaluated by R&D and QA leads
- Charles River Labs — Preclinical / Toxicology
- Unique edge: In-house allergen immunology models
- Evaluated by Head of R&D for platform validation
✅ Do-Now Checklist
Connect with all decision makers on LinkedIn (links above)
Use this Moonlight Therapeutics sales trigger to tailor your email + DM with the Copy-My-Prompt block (Step 7)
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑Integrated IND & clinical trial management❑
PROOF_METRIC = ❑Reduced trial launch time by 30%❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Samir
COMPANY = Moonlight Therapeutics
DEPT = Clinical Development
SIZE = ≈ 30
BOTTLENECK = Regulatory complexity of initiating first-in-human peanut allergy trials
EVENT = $3M funding
DETAIL = FDA cleared the IND for MOON101
PAIN = Regulatory complexity of initiating first-in-human peanut allergy trials
SRC = https://vcnewsdaily.com/moonlight-therapeutics/venture-capital-funding/nzznysngtn
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ 50
EMP_EST = ≈ 30
REV_EST = ≈ $1M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ 30-person Clinical Development
Samir—noticed your Clinical Development team is ≈ 30.
That’s when Regulatory complexity of initiating first-in-human peanut allergy trials slows growth.
We helped ≈ TBD fix this with Integrated IND & clinical trial management.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ 50.
DM ≤45 words, TONE:
Saw your post about FDA cleared the IND for MOON101 — Regulatory complexity of initiating first-in-human peanut allergy trials.
Integrated IND & clinical trial management. Reduced trial launch time by 30%.
Quick chat?